Articles by Sean Milmo - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Sean Milmo

Quality by Design—Bridging the Gap between Concept and Implementation

As Europe strives to firmly incorporate quality-by-design principles, there are several key issues that still need to be addressed.
Apr 2, 2014

As Europe strives to firmly incorporate quality-by-design principles, there are several key issues that still need to be addressed.

European Union Packaging Safety Features Come into Effect

Manufacturers are taking measures to comply with new package safety rules.
Mar 2, 2014

Manufacturers are taking measures to comply with new package safety rules.

EMA Collaborates with HTA Assessment Networks

High technology assessments are having an impact on biosimilars development in Europe.
Feb 2, 2014

High technology assessments are having an impact on biosimilars development in Europe.

Early Communication with Regulators is Essential for SMEs

With SMEs gaining wider recognition as the powerhouse of research and innovation in Europe, regulatory agencies are urging companies to engage with regulators early in the drug-development process.
Jan 2, 2014

With SMEs gaining wider recognition as the powerhouse of research and innovation in Europe, regulatory agencies are urging companies to engage with regulators early in the drug-development process.

Regulation of Biosimilars: A Matter of Variability, Similarity, and Comparability

As the European Union takes a closer look at its biosimilars guidelines, some key issues are proving difficult to resolve.
Dec 2, 2013

The European Union is strengthening its pioneering role in the regulation of biosimilars by further developing the basic rules for determining the levels of compatibility for this group of drugs. There are, however, some key issues that are not easy to resolve, as evident in a recent workshop on biosimilars organized by the European Medicines Agency (EMA).

European Union Introduces GMPs for Excipients

Regulators hope new standards will stop illegal drug imports, but manufacturers fear they may stifle innovation.
Nov 2, 2013

Regulators hope new standards will stop illegal drug imports, but manufacturers fear they may stifle innovation.

EU Raises API Standards: A Curse in Disguise?

The aim of the European Falsified Medicines Directive is to improve the quality of imported APIs, but does the pain now outweigh the gain?
Sep 2, 2013

The aim of the European Falsified Medicines Directive is to improve the quality of imported APIs, but does the pain now outweigh the gain?

Seeking Harmonization in Nanomedicines Regulatory Framework

Nanomedicines have been authorized by European licensing agencies for more than 30 years but are still posing regulatory difficulties.
Aug 2, 2013

Nanomedicines have been authorized by European licensing agencies for more than 30 years but are still posing regulatory difficulties.

EU Battles Medicine Shortages

European governments are under pressure to take regulatory action, but solving the problem of medicine shortages is not as straightforward as it seems.
Jul 2, 2013

European governments are under pressure to take regulatory action, but solving the problem of medicine shortages is not as straightforward as it seems.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
26%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
FindPharma Custom Search
Click here